Overview

• Presentation reportedly slated for the CDC’s vaccine advisory committee next week to inform possible changes for children, adolescents and pregnant women, with no decision yet.
• The analysis is said to rely on VAERS submissions, which are unverified and do not prove causation, while broader surveillance has identified only a rare myocarditis risk in young males.
• HHS described the unpublished claims as speculation, and officials have not disclosed the full methodology behind the analysis.
• Any committee recommendation would influence eligibility for updated shots and whether insurers cover them, with potential effects on routine access.
• Shares of Pfizer fell 3.94%, Moderna 7.40% and Novavax 3.56% after the leak, and Moderna said regulators in more than 90 countries have found no new safety issues in children or pregnant women.